Ignite Creation Date:
2024-05-06 @ 2:11 PM
Last Modification Date:
2024-10-26 @ 1:26 PM
Study NCT ID:
NCT04240002
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2020-01-21
Brief Title:
A Study of Gilteritinib ASP2215 Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 FLT3Internal Tandem Duplication ITD Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-01-21
First Submit QC Date:
January 21 2020
Study First Post Date:
2020-01-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-25
Last Update Post Date:
2024-07-01
Last Update Post Date Type:
ACTUAL